Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes

References

• Brodie A. 2002. Aromatase inhibitors in breast cancer. Trend Endocrinol Metab 13:61–5.
   PubMedGoogle Scholar
• Brodie AM. 1985. Aromatase inhibition and its pharmacologic implications. Biochem Pharmacol 34:3213–19.
   PubMed Web of Science ®Google Scholar
• Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Kamataki T. 2004. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25:2451–8.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–802.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 2003. Cytochromes P450, drugs, and diseases. Mol Interven 3:194–204.
   PubMedGoogle Scholar
• Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T. 2005. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60:855–7.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trend Pharmacol Sci 25:193–200.
   PubMed Web of Science ®Google Scholar
• Jeong S, Woo MM, Flockhart DA, Desta Z. 2009. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 64:867–875.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, Nakagawa K, Honda G, Ishizaki T, Kamataki T. 2003. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 13:689–95.
   PubMedGoogle Scholar
• Marfil F, Pineau V, Sioufi A, Godbillon SJ. 1996. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid–solid extraction and fluorescence detection. J Chromatograph B Biomed Appl 683:251–8.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. 2002. Clinical importance of the cytochromes P450. Lancet 360:1155–62.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18.
   PubMedGoogle Scholar
• Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, Nagashima K, Funae Y, Green C, Kinoshita M, Kamataki T. 1998. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8:239–49.
   PubMedGoogle Scholar
• Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8.
   PubMed Web of Science ®Google Scholar
• Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C, Duval M, Hornberger U. 2001. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharmaceut Drug Disposit 22: 191–7.
   PubMed Web of Science ®Google Scholar
• Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
   PubMed Web of Science ®Google Scholar
• Sioufi A, Gauducheau N, Pineau V, Marfil F, Jaouen A, Cardot JM, Godbillon J, Czendlik C, Howald H, Pfister C, Vreeland F. 1997a. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharmaceut Drug Disposit 18:779–89.
   PubMed Web of Science ®Google Scholar
• Sioufi A, Sandrenan N, Godbillon J, Trunet P, Czendlik C, Howald H, Pfister C, Ezzet F. 1997b. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharmaceut Drug Disposit 18:489–97.
   PubMed Web of Science ®Google Scholar
• Swinney DC. 1990. Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5α-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat. Drug Metab Disposit 18:859–65.
   PubMed Web of Science ®Google Scholar
• Tinel M, Belghiti J, Descatoire V, Amouyal G, Letteron P, Geneve J, Larrey D, Pessayre D. 1987. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem Pharmacol 36:951–5.
   PubMed Web of Science ®Google Scholar
• Toide K, Terauchi Y, Fujii T, Yamazaki H, Kamataki T. 2004. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol 67: 1269–78.
   PubMed Web of Science ®Google Scholar
• Wirtz B, Valles B, Parkinson A, Madan A, Probst A, Zimmering S, Gut J. 1996. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. Proceedings of the 7th North American ISSX Meeting, 10. p. 359.
   Google Scholar
• Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, Tyndale RF. 2002. An in Vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Comm 290:318–24.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. 2004. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 19:120–9.
   PubMedGoogle Scholar
• Yamazaki H, Inoue K, Hashimato M, Shimada T. 1999a. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archiv Toxicol 73:65–70.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. 1997. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Archiv Biochem Biophys 346:161–9.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Tanaka M, Shimada T. 1999b. Highly sensitive HPLC assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. J Chromatograph B Biomed Appl 721:13–19.
   PubMed Web of Science ®Google Scholar